31.68
2.63%
-0.95
Ionis Pharmaceuticals Inc stock is traded at $31.68, with a volume of 557.58K.
It is down -2.63% in the last 24 hours and down -9.15% over the past month.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
See More
Previous Close:
$32.63
Open:
$32.56
24h Volume:
557.58K
Relative Volume:
0.38
Market Cap:
$5.15B
Revenue:
$803.07M
Net Income/Loss:
$-358.81M
P/E Ratio:
-12.98
EPS:
-2.44
Net Cash Flow:
$-374.21M
1W Performance:
-0.40%
1M Performance:
-9.15%
6M Performance:
-32.13%
1Y Performance:
-35.87%
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Name
Ionis Pharmaceuticals Inc
Sector
Industry
Phone
(760) 931-9200
Address
2855 GAZELLE COURT, CARLSBAD, CA
Compare IONS with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
31.79 | 5.15B | 803.07M | -358.81M | -374.21M | -2.44 |
VRTX
Vertex Pharmaceuticals Inc
|
473.86 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
716.63 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
ARGX
Argen X Se Adr
|
651.92 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
275.00 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
118.86 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-02-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Jul-24-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
Jul-16-24 | Resumed | Jefferies | Buy |
Jun-14-24 | Upgrade | Bernstein | Underperform → Mkt Perform |
Apr-10-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
Jan-02-24 | Upgrade | BofA Securities | Neutral → Buy |
Oct-23-23 | Upgrade | BofA Securities | Underperform → Neutral |
Sep-29-23 | Initiated | Raymond James | Strong Buy |
Jul-31-23 | Upgrade | Citigroup | Neutral → Buy |
Jun-07-23 | Resumed | Piper Sandler | Overweight |
May-04-23 | Upgrade | Citigroup | Sell → Neutral |
Mar-21-23 | Initiated | Bernstein | Underperform |
Dec-21-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Sep-09-22 | Resumed | Morgan Stanley | Overweight |
Jul-18-22 | Resumed | Oppenheimer | Outperform |
Mar-31-22 | Resumed | Piper Sandler | Overweight |
Mar-01-22 | Initiated | Citigroup | Sell |
Mar-01-22 | Initiated | Guggenheim | Buy |
Feb-01-22 | Downgrade | BofA Securities | Buy → Underperform |
Dec-14-21 | Upgrade | William Blair | Mkt Perform → Outperform |
May-07-21 | Upgrade | UBS | Sell → Neutral |
Mar-01-21 | Upgrade | Barclays | Underweight → Equal Weight |
Dec-16-20 | Initiated | UBS | Sell |
Dec-15-20 | Upgrade | Cowen | Market Perform → Outperform |
Sep-14-20 | Resumed | JP Morgan | Neutral |
Sep-02-20 | Initiated | The Benchmark Company | Hold |
Jun-01-20 | Resumed | Oppenheimer | Outperform |
May-13-20 | Initiated | RBC Capital Mkts | Outperform |
Mar-05-20 | Initiated | Citigroup | Buy |
Dec-13-19 | Initiated | Oppenheimer | Outperform |
Nov-13-19 | Initiated | BofA/Merrill | Buy |
Nov-07-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
Sep-10-19 | Upgrade | Bernstein | Mkt Perform → Outperform |
Aug-08-18 | Reiterated | Stifel | Hold |
Aug-07-18 | Reiterated | Stifel | Hold |
May-08-18 | Downgrade | Evercore ISI | Outperform → In-line |
Oct-06-17 | Resumed | Goldman | Sell |
Aug-17-17 | Initiated | Evercore ISI | Outperform |
Aug-09-17 | Reiterated | Stifel | Hold |
Mar-10-17 | Downgrade | Goldman | Neutral → Sell |
Dec-28-16 | Reiterated | BMO Capital Markets | Outperform |
Dec-27-16 | Reiterated | Leerink Partners | Mkt Perform |
View All
Ionis Pharmaceuticals Inc Stock (IONS) Latest News
Ionis Pharmaceuticals EVP sells $194,939 in stock - MSN
Insider Sell: Brett Monia Sells Shares of Ionis Pharmaceuticals Inc (IONS) - GuruFocus.com
Insider Sell: Patrick O'neil Sells Shares of Ionis Pharmaceutica - GuruFocus.com
Ionis Pharmaceuticals CEO sells $1.23 million in stock - MSN
Ionis Pharmaceuticals CEO sells $1.23 million in stock By Investing.com - Investing.com Canada
EVP CLO & General Counsel O'Neil Patrick R. sold $194,939 worth of shares (6,165 units at $31.62), decreasing direct ownership by 10% to 57,452 units (SEC Form 4) - Quantisnow
Elizabeth L. Hougen Sells 1,523 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Stock - MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Sells $44,167.77 in Stock - MarketBeat
Brett P. Monia Sells 13,242 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Stock - MarketBeat
DAVENPORT & Co LLC Cuts Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Hereditary Transthyretin Amyloidosis (hATTR) Market Growth Projections 2023-2032: DelveInsight Analysis | Eidos, Corino, Prothena, Ionis Pharma, AstraZeneca, Novo Nordisk - Barchart
Amyotrophic Lateral Sclerosis Market Expected to Experience Major Growth by 2034, According to DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharma - Barchart
Hereditary Transthyretin Amyloidosis (hATTR) Market Growth - openPR
Biogen wins U.S. EU review for higher dose version of SMA drug marketed with Ionis - MSN
Ionis to hold fourth quarter and full year 2024 financial results webcast - BioSpace
Angioedema Pipeline 2024: Therapies Under Investigation, - openPR
Insider Sell Alert: C Bennett Sells Shares of Ionis Pharmaceuticals Inc (IONS) - GuruFocus.com
Insider Sell Alert: Brett Monia Sells Shares of Ionis Pharmaceuticals Inc (IONS) - GuruFocus.com
Insider Sell: Elizabeth Hougen Sells Shares of Ionis Pharmaceuti - GuruFocus.com
Insider Sell Alert: Eugene Schneider Sells Shares of Ionis Pharm - GuruFocus.com
EVP Research Swayze Eric sold $44,162 worth of shares (1,367 units at $32.31) and was granted 3,714 shares, increasing direct ownership by 5% to 48,017 units (SEC Form 4) - Quantisnow
EVP, Chf Clinical Develop Ofcr Schneider Eugene was granted 4,032 shares and sold $47,780 worth of shares (1,484 units at $32.20), increasing direct ownership by 4% to 61,056 units (SEC Form 4) - Quantisnow
Ionis Pharmaceuticals (NASDAQ:IONS) Reaches New 12-Month LowHere's Why - MarketBeat
SG Americas Securities LLC Boosts Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Ionis Pharmaceuticals (NASDAQ:IONS) Shares Gap DownTime to Sell? - MarketBeat
Ionis announces European licensing agreement with Otsuka for don - GuruFocus.com
10 Promising Biotech Stocks to Invest in (February 2025) - Securities.io
Ionis Pharmaceuticals Says Data Readout From Pelacarsen Study Is Delayed -January 31, 2025 at 01:17 pm EST - Marketscreener.com
Ionis stock slips as Novartis delays heart drug trial (NVS) - Seeking Alpha
Familial Chylomicronemia Syndrome FDA Approvals, Clinical - openPR
September 19th Options Now Available For Ionis Pharmaceuticals - Nasdaq
Ionis Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Ionis Pharmaceuticals (NASDAQ:IONS) Shares Up 7%Time to Buy? - MarketBeat
FDA & EMA Accept Biogen's Filings for Higher Dose SMA Drug - Yahoo Finance
What is Leerink Partnrs’ Forecast for IONS FY2024 Earnings? - Defense World
Spinocerebellar Ataxias Pipeline 2024: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma - Barchart
70+ Key Companies Advancing in Dry Age-Related Macular Degeneration Clinical Trial Therapeutic Space | DelveInsight - Yahoo Finance
Ionis stock rises on FDA, EMA nod for SMA drug dose increase - MSN
William Blair Brokers Increase Earnings Estimates for IONS - MarketBeat
Biogen/ Ionis Spinraza being reviewed for higher dose (BIIB) - Seeking Alpha
Leerink Partnrs Has Negative Outlook of IONS FY2024 Earnings - MarketBeat
Ionis Pharmaceuticals Insiders Sold US$3.2m Of Shares Suggesting Hesitancy - Simply Wall St
Transthyretin Amyloid Cardiomyopathy Treatment Market - openPR
Assenagon Asset Management S.A. Raises Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Position Boosted by Assenagon Asset Management S.A. - Defense World
Ionis Pharmaceuticals EVP sells $241,628 in stock - MSN
Ionis Pharmaceuticals EVP Brian Birchler sells $176,580 in stock - MSN
Ionis Pharmaceuticals exec sells $144,861 in stock - MSN
Ionis Pharmaceuticals EVP Eric Swayze sells $235,678 in stock - MSN
Ionis Pharmaceuticals Inc Stock (IONS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ionis Pharmaceuticals Inc Stock (IONS) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Monia Brett P | Chief Executive Officer |
Feb 04 '25 |
Sale |
31.65 |
38,843 |
1,229,463 |
180,683 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):